Alisertib

N/A

Report date: 2026/03/13 20:02:36
NME

Base Information

Drug NameAlisertib
Drug Alias Name阿利色替Alsertib阿利舍替AlisertibumAlisertib sodium +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase Aurora-A inhibitors
TargetsSerine/threonine-protein kinase Aurora-A
Therapy Area/IndicationsMetastatic breast cancerHormone-Resistant Prostate NeoplasmsSolid tumours +[85] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[34] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesTakeda Pharmaceutical Co LtdMillennium Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesTakeda Pharmaceuticals USA IncPuma Biotechnology IncNational Cancer Institute +[6] 
Inactive CompaniesThe University Of California DavisWeill Medical College of Cornell UniversityWashington University School Of Medicine +[8] 
Active IndicationsMetastatic breast cancerSolid tumoursSmall Cell Lung Carcinoma +[12] 
Inactive IndicationsHormone-Resistant Prostate NeoplasmsAngioimmunoblastic T-cell LymphomaMyelodysplastic Syndromes +[73] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG